Arrowhead Pharmaceuticals, Inc. (ARWR) stock
Close on Nov 12, 2026Market cap $6.66BP/E –Yield –
Arrowhead Pharmaceuticals, Inc. saw revenue fall 45.6% to $450.82M over the twelve months to Sep 30, 2026. Operating income fell 819.1% to -$707.17M, moving the operating margin from 11.9% to -156.9%. Free cash flow was -$283.94M, down 281.0% from a year earlier. At the latest close the market valued the company at $6.66B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $6.66B
- P/E ratio
- –
- Price to sales
- 14.77
- Price to book
- 132.37
- Dividend yield
- –
- Free cash flow yield
- -4.26%
Fundamentals
- Revenue
- $450.82M
- Net income
- -$724.21M
- EPS, diluted
- -$5.11
- Free cash flow
- -$283.94M
- Book value per share
- $0.35
- Diluted shares
- 143M
Trading
- Next earnings
- Nov 24, 2026 (estimated, during market hours)
- Previous close
- $49.36
- Open
- $48.99
- Day's range
- $46.98 – $48.99
- Volume
- 2,164,345
- Average volume (20 days)
- 1,900,117
- Index membership
- S&P MidCap 400 (since Feb 2026), Russell 1000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 1.69
- 52-week range
- $37.06 – $95.49
- RSI (14 days)
- 23.7
- Volatility (1 year)
- 63.0%
- Relative volume
- 1.12×
- WACC
- 13.3%
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ARWR | S&P 500 | Difference | ARWR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.4% | -2.7% | −19.7 pts | ||
| 3 months | -46.0% | -1.7% | −44.2 pts | ||
| Year to date | -29.0% | +11.9% | −40.9 pts | ||
| 1 year | +13.8% | +12.0% | +1.8 pts | ||
| 3 years | +74.9% | +78.2% | −3.3 pts | +20.5% | +21.2% |
| 5 years | -36.2% | +73.2% | −109.5 pts | -8.6% | +11.6% |
| 10 years | +1028.0% | +309.6% | +718.3 pts | +27.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Arrowhead Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Update
- Update
About Arrowhead Pharmaceuticals
Pharmaceutical Preparations
Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics designed to treat severe and intractable diseases by silencing disease-causing genes. The company utilizes its proprietary Targeted RNA Molecule (TRiM) platform to trigger targeted, catalytic gene knockdown across diverse tissue types beyond the liver, including adipose tissue, muscle, pulmonary tissue, and the central nervous system. Arrowhead's primary commercialized product is REDEMPLO (plozasiran), an FDA-approved medicine for adults with familial chylomicronemia syndrome, complemented by a clinical pipeline targeting cardiometabolic, pulmonary, renal, and neurodegenerative disorders. The company serves adult patients suffering from rare and high-prevalence genetic disorders directly and partners with major pharmaceutical companies through licensing and co-development collaborations.
Company profile, executives and historyArrowhead Pharmaceuticals stock: common questions
What is Arrowhead Pharmaceuticals's stock price?
ARWR closed at $47.15 on Nov 12, 2026, down 4.48% on the day. Over the past 52 weeks it traded between $37.06 and $95.49.
What is Arrowhead Pharmaceuticals's market cap?
Arrowhead Pharmaceuticals was worth $6.66B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ARWR's P/E ratio?
Arrowhead Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$5.11), so it has no meaningful P/E ratio.
How much revenue does Arrowhead Pharmaceuticals make?
Arrowhead Pharmaceuticals reported revenue of $450.82M for the twelve months to Sep 30, 2026, down 45.6% from a year earlier.
Does Arrowhead Pharmaceuticals pay a dividend?
No. Arrowhead Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Arrowhead Pharmaceuticals report earnings next?
Arrowhead Pharmaceuticals is expected to report Q4 FY2026 results on Nov 24, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ARWR stock performed over the past year?
Including dividends, ARWR returned +13.8% over the past year, against +12.0% for the S&P 500.
How many ARWR shares are sold short?
12M shares were sold short at the latest FINRA report, 8.54% of the float, or 8.5 days of average trading volume.
Who are Arrowhead Pharmaceuticals's competitors?
Companies most similar to Arrowhead Pharmaceuticals by business, industry and size include IONS, MIRM, KNSA, TVTX, BBIO.
See a number that looks wrong?